In the midst of a drug war in the Philippines, President Rodrigo Duterte has announced a crackdown on the illegal sale of counterfeit over-the-counter medicines. On March 28, Duterte ordered police to arrest anyone involved in the manufacture, import or distribution of falsified pharmaceuticals. The command followed a made by the Filipino Food and Drug Administration (FDA) and United Laboratories, which highlighted the difference between real and counterfeit medicine – in this case, Biogesic 500mg paracetamol tablets.
The FDA has continuously warned of the risk of counterfeit medicines to the economic and public health of the Philippines
The warning advised the public to identify modifications in the pill colour, foil patterns and illegible batch number markings on the packaging. Counterfeit medicine, however, is not exclusive to the Philippines: the World Health Organisation (WHO) estimates that in low and middle-income countries, are falsified, which are classified as non-FDA approved or intentionally misrepresenting an active ingredient.
The FDA has continuously warned of the risk of counterfeit medicines to the economic and public health of the Philippines. Some headway has been made to reduce their availability. In January, the FDA and the Philippine National Police over PHP 3m ($57,570) worth of counterfeit medicine in Sampaloc, Manila. The confiscated goods included 15 different brands of over-the-counter medication, which were manufactured by an unidentified local drug company.
Rae Ann Verona, a journalist covering Filipino domestic news, told World Finance that confiscation is not enough: “It’s a start, but they have to get to the source and look at the reasons why counterfeit medicine manufacturers, importers, and distributors are thriving.”
In November 2017, the WHO estimated that counterfeit medicine accounts for 10 percent of a $300bn industry in low and middle-income countries. Salvador Panelo, Chief Presidential Legal Counsel, recently suggested that the percentage could possibly reach an in developing countries. According to the FDA’s Regulatory Enforcement Unit, seized products that have been imported from China or India are sold, directly or via online transactions, at a low cost in order to reel in unwary small-time dealers. The counterfeit pharmaceutical industry in the Philippines is clearly lucrative, while the importation of fake drugs through various channels is an added burden for authorities.
Supply and demand is a key factor in driving the low price of counterfeit medicine compared with authentic drugs. “Counterfeit drug makers and suppliers will continue to distribute and manufacture as long as affordable medications are needed,” explained Verona. This is because affordable yet authentic medication is hard to find in the Philippines. Since 1985, at a faster rate than in neighbouring countries like Thailand, Malaysia and Indonesia. Furthermore, stated that 12 percent VAT and public pharmacy mark-ups, some as high as 30 percent, contribute to the unaffordability of generic medication.
Jovencio G Apostol, a professor of pharmacology at the University of Santo Tomas, observed: “Health insurance coverage of Filipinos is one of the lowest in Asia.” As such, pharmaceutical products of out-of-pocket expenditures in Filipino households. Counterfeit drug manufacturers have exploited this need for affordable medication to satisfy their own money-making objectives.
Verona further explained that falsified medicine has an especially detrimental effect in developing countries: “Fake drugs deliberately cheat the public, which is dangerous in all countries, but especially for countries like the Philippines where an unfortunate number of people still lack access to clean water and sanitation… [This] makes them susceptible to bacterial diseases, for example.” Counterfeit drugs or poor-quality medicine may add to antibiotic resistance, which threatens the development of life-saving drugs in the future.
The Filipino Government has implemented various policies over the years to reduce prices and increase the use of generic medicine. These include: the Generics Act of 1988, the 2000 Half-Priced Medicines Programme and the Universally Accessible Cheaper and Quality Medicine Act of 2008. However, these measures have not resolved the problem – mainly due to rigorous marketing strategies executed by dominant manufacturers and importers of branded generic medication – as prices have remained among the highest in Asia.
As long as Filipinos demand affordable medication, the manufacture and distribution of counterfeit and substandard drugs will continue. The public is becoming more aware of falsified drugs, especially with the recent case of fake paracetamol, which may reduce the sale of counterfeits. However, it is unclear how much of a difference that will make to the overall industry. The government is tackling the issue by arresting those involved but, in order to stop the circulation of fake drugs, it needs to regulate the exorbitant mark-up of authentic medicine.